Asahi Kasei Medical Acquires Bionova Scientific
Deal adds biopharma services to its capabilities
Asahi Kasei Medical, a bioprocess business that is also an entity of Asahi Kasei Group, has acquired Bionova Scientific, LLC, a contract development and manufacturing organization (CDMO).
The CDMO has a track record when it comes to developing next-generation antibody drugs. Among the features, its good manufacturing practice (GMP) manufacturing facility has state-of-the-art equipment including single-use bioreactors. Therefore, purchasing Bionova Scientific will enable Asahi Kasei Medical to add a biopharma CDMO to its bioprocess business. Being able to offer a broader range of services to this sector will allow the company to grow its bioprocess business more rapidly by better serving the industry and by reaching a wider range of customers.
Asahi Kasei Medical’s objective is to contribute to improved safety and efficient manufacture of biotherapeutics, and to further drive the growth of the healthcare sector of the Asahi Kasei Group.
